1. Medtech Insight
  2. >>Business
  3. >>Strategy

Novocure Transforms Patient Support System During Pandemic

 
• By Reed Miller

The company is running a pilot program to allow glioblastoma patients who use Novocure’s Optune Tumor Treating Fields device to download data from the device at home.

Soft and blurry image:Medical image MRI Brain showing There is diameter cystic mass or tumor at Left frontal lobe Glioblastoma at Lt frontal lobe with metastasis, brain metastases.
• Source: shutterstock.com

NovoCure Limited is adapting to the challenges created by the pandemic supporting patients who use its Tumor Treating Fields (TTF) devices to treat brain and lung cancer.

The company markets the Optune TTF device to treat glioblastomas, an aggressive type of brain tumor. It also markets the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

No EUDAMED, No Market: ‘Waiting Until Mandatory Deadline Is Risky’

 
• By Natasha Barrow

EirMed CEO Richard Houlihan warns that EUDAMED (the European database on medical devices) publication delays may harm medical device manufacturers. Currently, only a fraction of the required uploads have occurred, creating potential compliance risks as the mandatory deadline approaches.

Reports Put $4B Price Tag On Versius Maker CMR. Will This Change Surgical Robot Valuation?

 
• By Barnaby Pickering

The value proposition of surgical robots is quickly changing. Gone is the focus on benefit to patients; instead cost, operative efficiency and surgeon longevity are the new focal points, making deciphering M&A value much more difficult.

Tempus AI Buys Paige. AI For $81.25M To Help Build Largest Oncology Foundation Model

 
• By Marion Webb

Tempus expects its $81.25m acquisition of Paige AI to accelerate building the largest oncology foundation model. With its third deal this year, Tempus expands capabilities across genomics, pathology, and clinical trials.

SetPoint Medical Raises $140M: Pipeline Expansion And Multiple Sclerosis Clinical Trial On Horizon

 
• By Natasha Barrow

SetPoint Medical secured US FDA approval for its vagus nerve neuromodulation device to treat RA. Now, the start-up is tasked with convincing both rheumatologist and surgeons to adopt its technology over or alongside biologic drugs. CEO Murthy Simhambhatla talks exit strategy plans.

More from Business